<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">


Next generation sequencing

We offer a broad range of blood and tissue-based NGS solutions for our biopharma partners. 

NGS Platform Overview​

Next Generation Sequencing (NGS) is a high throughput, massively parallel sequencing technique that can generate large amounts of clinically relevant data. We offer you a broad range of blood and tissue-based NGS testing solutions, including comprehensive cell-free nucleic acid assays, tumor mutation burden testing, and immune response analyses. We use the ThermoFisher Ion GeneStudio™ S5 Prime system for sequencing and data analysis.

Key Benefits of NGS at Biodesix

icon-sample Blood & Tissue
Low Sample Input
bdx-clock-icon Fast Project Turnaround
3Asset 28 Custom Designed Assays
icon-target Highly Accurate
3Asset 31 FDA
handshake Partnership with Thermo Fisher Scientific

Oncomine™ Pan-Cancer Cell-Free Assay

  • Targeted plasma-based panel for the detection of actionable driver and resistance mutations with a low limit of detection down to 0.1%.

  • 52 genes, 272 amplicons, >900 hotspots and indels, fusions and copy number variations.

  • One 10 mL tube of whole blood.

  • Three-day workflow.

Download the gene list

Cancer-Specific Assays

Targeted plasma-based assays for the detection of actionable driver and resistance mutations with a low limit of detection down to 0.1%.

Oncomine Tumor Mutation Load Assay

  • TML is becoming a relevant predictive biomarker for response to immunotherapies.

  • Assay looks for 409 key cancer-driven genes, spanning 1.7 Mb of genomic space.

  • Requires as little as 20 ng of tumor DNA from FFPE.

  • Three-day workflow.

Download the TML gene list

Oncomine Immune Response Assay

  • Designed to measure the expression of 395 genes involved in tumor–immune system interactions.

  • These genes play important roles in the tumor microenvironment and are involved in functional pathways such as lymphocyte regulation, cytokine signaling, lymphocyte markers, checkpoint pathway, and tumor characterization.

  • Requires a minimum of 10 ng of total RNA isolated from FFPE tissue.

  • Three-day workflow.

Oncomine Immune Repertoire TCR Beta Assay

  • Measures the response to tumor antigens through clonal assessment of T-lymphocytes.
  • Short-read sequencing assay interrogates the CDR3 region of the TCR beta chain.
  • Compatible with both blood and FFPE.
  • Three-day workflow.

Get in touch

Contact us

What we do

Learn More

Data library

Discover more

Interested in another topic?